
Sellas Stock Jumps on Unconfirmed 80th Event in AML Trial While GPS Prospects Shine
Sellas Life Sciences’ stock surged after a German report claimed its Regal AML trial reached the 80th event, though the company has not confirmed the milestone and the official count remains at 78 with data still undergoing review. Optimism around GPS persists, helped by positive Moderna data on cancer vaccines, with initial SLS009 results expected in Q4. Sellas ended Q2 with $138.3 million cash; retail traders remain skeptical until official confirmation and regulatory filings, while a potential FDA BLA could follow if the milestone proves valid.












